BeOne Medicines AG/$ONC
1D1W1MYTD1Y5YMAX
Capital at risk
About BeOne Medicines AG
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
- Ticker
- $ONC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 12,000
- Headquarters
- Basel, Switzerland
- Website
- beonemedicines.com
ONC Metrics
BasicAdvanced
$40B
62.77
$5.59
0.50
-
Price and volume
Market cap
$40B
Beta
0.5
52-week high
$385.22
52-week low
$253.95
Average daily volume
393K
Financial strength
Current ratio
3.405
Quick ratio
2.911
Long term debt to equity
0.338
Total debt to equity
0.396
Interest coverage (TTM)
7.97%
Profitability
EBITDA (TTM)
1,071.609
Gross margin (TTM)
88.89%
Net profit margin (TTM)
10.70%
Operating margin (TTM)
15.06%
Effective tax rate (TTM)
24.46%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
7.46%
Return on equity (TTM)
14.66%
Valuation
Price to earnings (TTM)
62.769
Price to revenue (TTM)
6.347
Price to book
7.67
Price to tangible book (TTM)
7.76
Price to free cash flow (TTM)
29.719
Free cash flow yield (TTM)
3.36%
Free cash flow per share (TTM)
11.805
Growth
Revenue change (TTM)
34.35%
Earnings per share change (TTM)
-436.23%
3-year revenue growth (CAGR)
50.14%
10-year revenue growth (CAGR)
96.54%
3-year earnings per share growth (CAGR)
-30.51%
10-year earnings per share growth (CAGR)
1.54%
Bulls say / Bears say
Brukinsa global revenues reached $1.2 billion in Q2 2026, marking a 31% year-over-year increase and underscoring strong demand for BeOne’s flagship therapy. (Dow Jones Newswire)
Management raised full-year 2026 revenue guidance to $6.6 billion–$6.8 billion, a $300 million increase driven by Brukinsa’s global leadership, signaling confidence in sustained commercial growth. (Dow Jones Newswire)
The FDA granted accelerated approval to BEQALZI (sonrotoclax) for relapsed or refractory mantle cell lymphoma, diversifying BeOne’s commercial portfolio beyond its BTK inhibitor franchise. (BeOne 2Q 10-Q)
In 2025, Brukinsa accounted for approximately $3.9 billion of BeOne’s $5.3 billion total revenue (~74%), exposing the company to single-product concentration risk. (2025 Form 10-K)
Brukinsa faces intense competition from established BTK inhibitors, notably AbbVie’s Imbruvica and AstraZeneca’s Calquence, across key markets including the U.S., Europe, and China. (HKEX Competition Disclosure)
BeOne expects operating expenses to continue growing at a similar year-over-year rate into 2027 to fund pipeline advancement, which may constrain near-term margin expansion. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
Upcoming events
No upcoming events
ONC News
AllArticlesVideos
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
Business Wire3 weeks ago
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
Business Wire3 weeks ago
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
Business Wire3 weeks ago
Funds containing ONC
AllGBPEURUSD
Fund name | Fund size | $ONC weighting |
|---|---|---|
iShares China Large Cap£FXC | £624M | 1.87% |
iShares Dow Jones China Offshore 50€EXXU | €42M | 1.75% |
iShares MSCI China€ICGA | €2.3B | 0.88% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.77% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.77% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.